Known targets — ChEMBL curated mechanism
ACHEADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3APH1AAPH1BCHRM2CHRM3EZH2GRIN2AHTR1AHTR1BHTR1DHTR1FHTR3ANCSTNP2RY12PSEN1PSEN2PSENENSIGMAR1SLC6A2SLC6A3SLC6A4
The experimentally established mechanism targets of 2-Pyrrolidone. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| 2-Pyrrolidone SCHEMBL4367304 | 1.00 | — | — | |
| 2-Pyrrolidone SCHEMBL1048019 | 1.00 | OR51E2 (0.94) | — | |
| 2-Pyrrolidone SCHEMBL28877688 | 0.97 | — | — | |
| 2-Pyrrolidone SCHEMBL28933712 | 0.97 | — | — | |
| 2-Pyrrolidone SCHEMBL9441874 | 0.97 | — | — | |
| 2-Pyrrolidone SCHEMBL27827832 | 0.97 | — | — | |
| 2-Pyrrolidone SCHEMBL4299593 | 0.97 | — | — | |
| 2-Pyrrolidone SCHEMBL9304498 | 0.97 | OR51E2 (1.00) | — | |
| 2-Pyrrolidone SCHEMBL2389 | 0.97 | — | — | |
| 2-Pyrrolidone SCHEMBL2167448 | 0.97 | OR51E2 (1.00) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 436 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-120004697-A | Preparation method of OrgVO material and application of OrgVO material as secondary battery anode material | 同济大学 | 2025-05-16 | — | — | CN | claimed |
| CN-105732563-A | Novel method for synthesizing 9- bromine-3-(2-bromoacetyl)-10,11-dihydro-5H-dibenzo [c, g] chromene-8(9h)-ketone | 江苏苏利精细化工股份有限公司 | 2016-07-06 | — | — | CN | claimed |
| EP-2324830-A1 | Process for the preparation of a monocyclic azole derivative that inhibits the interaction of ligands with rage | TransTech Pharma Inc. (US) | 2011-05-25 | — | — | EP | claimed |
| EP-0743574-B1 | Migration imaging members | XEROX CORP (US) | 2000-12-27 | — | — | EP | claimed |
| EP-0743573-B1 | Method for obtaining image contrast migration imaging members | XEROX CORP (US) | 2000-09-06 | — | — | EP | claimed |
| EP-0743574-A2 | Migration imaging members | XEROX CORPORATION (US) | 1996-11-20 | — | — | EP | claimed |
| EP-0743573-A2 | Method for obtaining image contrast migration imaging members | XEROX CORPORATION (US) | 1996-11-20 | — | — | EP | claimed |
| US-5563014-A | SOFTENABLE LAYER CONTAINIG PHOTOSENSITIVE MARKING MATERIAL; TRANSPARENTIZING AGENT | XEROX CORPORATION (US) | 1996-10-08 | — | — | US | claimed |
| US-5514505-A | SELECTIVE TRANSPARENTIZATION OF PHOTOSENSITIVE MIGRATION MARKING PARTICLES EMBEDDED NEAR THE SURFACE OF A SOFTENABLE LAYER SUPPORTED BY AN ELECTROCONDUCTIVE SUBSTRATE | XEROX CORPORATION (US) | 1996-05-07 | — | — | US | claimed |
| EP-0486734-B1 | 1-Aryl-1-hydroxy-1-substituted-3-(4-substituted-1-piperazinyl)-2-propanones and their use in treatment of neurogenic bladder disorders | MARION MERRELL DOW INC (US) | 1995-08-30 | — | — | EP | claimed |
| EP-0486734-A1 | 1-Aryl-1-hydroxy-1-substituted-3-(4-substituted-1-piperazinyl)-2-propanones and their use in treatment of neurogenic bladder disorders | MARION MERRELL DOW INC. (US) | 1992-05-27 | — | — | EP | claimed |
| EP-0089894-B1 | N-(2-(4-HYDROXY-3-METHOXY-PHENYL)-2-HYDROXY-ETHYL)-3-AMINO-1(1-BENZIMIDAZOLYL) BUTANE AND SALTS AND HYDRATES WITH BETA-ADRENERGIC ACTIVITY, THERAPEUTICAL APPLICATIONS AND PROCESS FOR THEIR PREPARATION | Société anonyme dite: LABORATOIRE ROGER BELLON (FR) | 1986-06-11 | — | — | EP | claimed |
| JP-59196891-A | — | — | None | — | — | JP | disclosed |
| US-12570672-B2 | Macrocyclic compounds and methods of use | AMGEN INC. | 2026-03-10 | — | — | US | disclosed |
| EP-4683918-A1 | NLRP3 INFLAMMASOME INHIBITORS AND USES THEREOF | Insilico Medicine IP Limited (HK) | 2026-01-28 | — | — | EP | disclosed |
| US-20250304599-A1 | MACROCYCLIC COMPOUNDS AND METHODS OF USE | AMGEN INC. (US) | 2025-10-02 | — | — | US | disclosed |
| US-3959290-A | ANALGESICS, NARCOTIC ANTAGONISTS | BRISTOL-MYERS COMPANY (US) | 1976-05-25 | — | — | US | disclosed |
| US-3956336-A | NARCOTIC ANTAGONIST, ANALGESICS | BRISTOL-MYERS COMPANY (US) | 1976-05-11 | — | — | US | disclosed |
| US-3943173-A | 3-Alkylamino- alpha-aminomethyl-4-hydroxybenzyl alcohols | SMITHKLINE CORPORATION (US) | 1976-03-09 | — | — | US | disclosed |
| US-3933913-A | N,N'-bis[3-substituted-4-hydroxypheyl)-2-hydroxyethyl)]-polymethylenediamines | SMITHKLINE CORPORATION (US) | 1976-01-20 | — | — | US | disclosed |